Prognostic indicators for naïve canine non‐indolent T‐cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy

Blaxill, John; Buzzacott, Peter; Finlay, Jessica Renee

doi:10.1111/vco.12768

Cited by 7 publications

(7 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparing this finding to previous literature is challenging as the prognostic significance of stage V lymphoma in dogs is unclear and may vary depending on type of lymphoma 42 ; whilst some studies associate stage V disease with poorer survival, other studies find no relationship between stage and outcome. [43][44][45][46] Similar to our study, PB but not BM involvement was significantly associated with survival in feline LGLL. 41 It is therefore possible that stage V disease, particularly PB involvement, has more prognostic relevance in LGLL compared to other lymphoma types and warrants further investigation in future studies.…”

Section: Mostsupporting

confidence: 82%

“…Dogs with PB involvement had shorter PFI and OST on multivariable analysis. Comparing this finding to previous literature is challenging as the prognostic significance of stage V lymphoma in dogs is unclear and may vary depending on type of lymphoma 42 ; whilst some studies associate stage V disease with poorer survival, other studies find no relationship between stage and outcome 43–46 . Similar to our study, PB but not BM involvement was significantly associated with survival in feline LGLL 41 .…”

Section: Discussionsupporting

confidence: 65%

See 1 more Smart Citation

Large granular lymphocyte lymphoma in 65 dogs (2005–2023)

Yale,

Crawford,

Gramer

et al. 2023

Vet Comparative Oncology

View full text Add to dashboard Cite

Large granular lymphocyte lymphoma (LGLL) is a rare form of lymphoma in dogs. Limited information exists regarding presentation, treatment response, and outcome. The aim of this single‐institute, retrospective study was to characterise clinical presentation, biologic behaviour, outcomes, and prognostic factors for dogs with LGLL. Cytologic review was also performed. Sixty‐five dogs were included. The most common breed was the Labrador retriever (29.2%), and the most common presenting signs were lethargy (60.0%) and hyporexia (55.4%). The most common primary anatomic forms were hepatosplenic (32.8%) and gastrointestinal (20.7%). Twenty dogs (30.8%) had peripheral blood or bone marrow involvement. Thirty‐two dogs were treated with maximum tolerated dose chemotherapy (MTDC) with a response documented in 74.1% of dogs. Dogs ≥7 years, and those with neutropenia or thrombocytopenia at diagnosis had the reduced likelihood of response to treatment. For dogs treated with MTDC median progression‐free interval (PFI) was 17 days (range, 0–481), the median overall survival time (OST) 28 days (range, 3–421), and the 6‐month and 1‐year survival rates were 9.4% and 3.1%, respectively. On multivariable analysis, monocytosis and peripheral blood involvement were significantly associated with shorter PFI and OST. Long‐term survival (≥100 days) was significantly associated with intermediate lymphocyte size on cytology. Dogs with LGLL have moderate response rates to chemotherapy but poor overall survival. Additional studies are needed to further evaluate prognostic factors and guide optimum treatment recommendations.

show abstract

Section: Mostsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 65%

Large granular lymphocyte lymphoma in 65 dogs (2005–2023)

Yale,

Crawford,

Gramer

et al. 2023

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…There was variability in the exclusion criteria regarding treatment prior to the use of chemotherapy. Only patients that had not received prior chemotherapy were included in 85 papers with 107 groups involving 5269 cases [ 5 , 9 , 10 , 12 , 15 , 18 , 30 , 36 , 38 , 43 , 49 , 54 , 55 , 56 , 57 , 60 , 62 , 63 , 69 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 ,…”

Section: Resultsmentioning

confidence: 99%

“…Of these, 3 papers with 3 groups included 107 cases treated with a CHOP-like protocol [ 100 , 123 , 126 ]. Two papers with 2 groups and 102 cases used a MOPP-type protocol [ 79 , 100 ], and the remainder had various protocols used [ 91 , 159 , 176 ]. The group sizes ranged from 13 to 127.…”

Section: Resultsmentioning

confidence: 99%

Review of Canine Lymphoma Treated with Chemotherapy—Outcomes and Prognostic Factors

Bennett

Williamson

Taylor

2023

Veterinary Sciences

View full text Add to dashboard Cite

While canine lymphoma is a relatively common and important disease seen by veterinarians, there are limited comprehensive reviews of the literature regarding the remission and survival times following chemotherapy, and the associated prognostic factors. This comprehensive thematic review covers the available veterinary literature covering treatment outcomes and identified prognostic factors. A lack of standardised approaches to evaluate and report the outcomes was identified, including factors that would alter the duration of responses by weeks, or occasionally months. After publication of the suggested reporting criteria, this has improved but is still not uniformly applied. The prognostic factors included for evaluation varied from as few as three to seventeen, with over 50 studies using only univariate analysis. Individual papers reported much longer outcomes than others, but assessing the outcomes overall, there has been minimal change over the last 40 years. This supports the belief that novel approaches for lymphoma therapy will be required to substantively improve outcomes.

show abstract

“…It is also possible associations exist that our study did not have the power to detect. Adequately powered, randomized controlled trials are also needed to determine if alternative protocols, such as LOPP, 30,33,34 result in improved outcomes for TCL patients.…”

Section: Methodsmentioning

confidence: 99%

Calculation of dose intensity and comparison of published methods using a cohort of canine T‐cell lymphoma patients undergoing CHOP‐based chemotherapy

Lenz

Benjamin

Walsh

et al. 2023

Vet Comparative Oncology

View full text Add to dashboard Cite

Methods of calculating and reporting dose intensity (DI) of CHOP‐based protocols in the veterinary literature vary. The goal of this retrospective study is to examine the prognostic significance of the average percentage of planned DI received in a cohort of canine T‐cell lymphoma patients treated with a modified CHOP protocol with corresponding toxicity and efficacy data. Our data set of 40 dogs was analysed using various previously published methods for calculating DI. Median progression‐free survival and overall survival were 91 and 196 days, respectively. Receiving a higher percentage of planned DI was not found to be associated with patient outcome. Outcomes remain poor for dogs with T‐cell lymphoma treated with CHOP‐based chemotherapy irrespective of received DI. Standard methods of DI calculation and reporting should be adopted in veterinary oncology to enable repeatable and rigorous comparisons of published chemotherapy protocols and to ascertain the potential prognostic relevance of DI in canine lymphoma patients.

show abstract

Prognostic indicators for naïve canine non‐indolent T‐cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy

Cited by 7 publications

References 49 publications

Large granular lymphocyte lymphoma in 65 dogs (2005–2023)

Large granular lymphocyte lymphoma in 65 dogs (2005–2023)

Review of Canine Lymphoma Treated with Chemotherapy—Outcomes and Prognostic Factors

Calculation of dose intensity and comparison of published methods using a cohort of canine T‐cell lymphoma patients undergoing CHOP‐based chemotherapy

Contact Info

Product

Resources

About